Cargando…
Vaccine design and delivery approaches for COVID-19
COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of time and cost in fighting this disease. In this regard, today's scientific knowledge shows that designing and prod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380485/ https://www.ncbi.nlm.nih.gov/pubmed/34454291 http://dx.doi.org/10.1016/j.intimp.2021.108086 |
_version_ | 1783741206257205248 |
---|---|
author | Shahzamani, Kiana Mahmoudian, Fatemeh Ahangarzadeh, Shahrzad Ranjbar, Mohammad Mehdi Beikmohammadi, Leila Bahrami, Samira Mohammadi, Elmira Esfandyari, Sahar Alibakhshi, Abbas Javanmard, Shaghayegh Haghjooy |
author_facet | Shahzamani, Kiana Mahmoudian, Fatemeh Ahangarzadeh, Shahrzad Ranjbar, Mohammad Mehdi Beikmohammadi, Leila Bahrami, Samira Mohammadi, Elmira Esfandyari, Sahar Alibakhshi, Abbas Javanmard, Shaghayegh Haghjooy |
author_sort | Shahzamani, Kiana |
collection | PubMed |
description | COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of time and cost in fighting this disease. In this regard, today's scientific knowledge shows that designing and producing an effective vaccine is the best possible way to diminish the disease burden and dissemination or even eradicate the disease. Due to the urgent need, many vaccines are now available earlier than scheduled. New technologies have also helped to produce much more effective vaccines, although the potential side effects must be taken into account. Thus, in this review, the types of vaccines and vaccine designs made against COVID-19, the vaccination programs, as well as the delivery methods and molecules that have been used to deliver some vaccines that need a carrier will be described. |
format | Online Article Text |
id | pubmed-8380485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83804852021-08-23 Vaccine design and delivery approaches for COVID-19 Shahzamani, Kiana Mahmoudian, Fatemeh Ahangarzadeh, Shahrzad Ranjbar, Mohammad Mehdi Beikmohammadi, Leila Bahrami, Samira Mohammadi, Elmira Esfandyari, Sahar Alibakhshi, Abbas Javanmard, Shaghayegh Haghjooy Int Immunopharmacol Article COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of time and cost in fighting this disease. In this regard, today's scientific knowledge shows that designing and producing an effective vaccine is the best possible way to diminish the disease burden and dissemination or even eradicate the disease. Due to the urgent need, many vaccines are now available earlier than scheduled. New technologies have also helped to produce much more effective vaccines, although the potential side effects must be taken into account. Thus, in this review, the types of vaccines and vaccine designs made against COVID-19, the vaccination programs, as well as the delivery methods and molecules that have been used to deliver some vaccines that need a carrier will be described. Elsevier B.V. 2021-11 2021-08-23 /pmc/articles/PMC8380485/ /pubmed/34454291 http://dx.doi.org/10.1016/j.intimp.2021.108086 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Shahzamani, Kiana Mahmoudian, Fatemeh Ahangarzadeh, Shahrzad Ranjbar, Mohammad Mehdi Beikmohammadi, Leila Bahrami, Samira Mohammadi, Elmira Esfandyari, Sahar Alibakhshi, Abbas Javanmard, Shaghayegh Haghjooy Vaccine design and delivery approaches for COVID-19 |
title | Vaccine design and delivery approaches for COVID-19 |
title_full | Vaccine design and delivery approaches for COVID-19 |
title_fullStr | Vaccine design and delivery approaches for COVID-19 |
title_full_unstemmed | Vaccine design and delivery approaches for COVID-19 |
title_short | Vaccine design and delivery approaches for COVID-19 |
title_sort | vaccine design and delivery approaches for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380485/ https://www.ncbi.nlm.nih.gov/pubmed/34454291 http://dx.doi.org/10.1016/j.intimp.2021.108086 |
work_keys_str_mv | AT shahzamanikiana vaccinedesignanddeliveryapproachesforcovid19 AT mahmoudianfatemeh vaccinedesignanddeliveryapproachesforcovid19 AT ahangarzadehshahrzad vaccinedesignanddeliveryapproachesforcovid19 AT ranjbarmohammadmehdi vaccinedesignanddeliveryapproachesforcovid19 AT beikmohammadileila vaccinedesignanddeliveryapproachesforcovid19 AT bahramisamira vaccinedesignanddeliveryapproachesforcovid19 AT mohammadielmira vaccinedesignanddeliveryapproachesforcovid19 AT esfandyarisahar vaccinedesignanddeliveryapproachesforcovid19 AT alibakhshiabbas vaccinedesignanddeliveryapproachesforcovid19 AT javanmardshaghayeghhaghjooy vaccinedesignanddeliveryapproachesforcovid19 |